AA
XERS icon

AlphaCentric Advisors’s Xeris Biopharma Holdings XERS Stock Holding History

AlphaCentric Advisors’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$369K Buy
46,549
+663
+1% +$4.23K 0.31% 112
2026
Q1 		$266K Buy
45,886
+2,494
+6% +$16.5K 0.27% 119
2025
Q4 		$341K Buy
+43,392
New +$342K 0.34% 96

Other funds holding XERS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

AlphaCentric Advisors's XERS Position: Q2 2026 in Review

AlphaCentric Advisors increased its Xeris Biopharma Holdings (XERS) stake by 1.4% in Q2 2026, buying an estimated $4.23K and bringing the position to 46,549 shares worth $369K. The position accounts for 0.31% of the portfolio, ranked #112.

AlphaCentric Advisors first reported a position in XERS in Q4 2025 and has held it in 3 quarters since. 241 funds tracked by Wall St. Rank hold XERS as of Q2 2026.

  • AlphaCentric Advisors held 46,549 shares of Xeris Biopharma Holdings worth $369K as of Q2 2026.
  • AlphaCentric Advisors bought 663 Xeris Biopharma Holdings shares in Q2 2026, an estimated $4.23K.
  • Xeris Biopharma Holdings made up 0.31% of AlphaCentric Advisors's portfolio in Q2 2026, its #112 holding.
  • AlphaCentric Advisors first reported a position in Xeris Biopharma Holdings in Q4 2025 and has held it in 3 quarters since.
  • 241 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2026.

Based on AlphaCentric Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.